2016 Review: Pricing, R&D Issues Dominate China Commercial Arena
Executive Summary
2016 was again another busy year on the commercial front in China, with market changes, new regulations, and ongoing pricing pressures all affecting the pharma sector. Meanwhile, the push for licensing deals, innovation, and international expansion continued apace.
You may also be interested in...
DTP Pharmacies March On In China: Pharma Ignores At Its Own Risk
A shift in dispensing from hospitals to external pharmacies has led to predictions that the direct-to-patient sales model will be big in China. But only those with the right partnerships and expertise will reap the benefits, leading pharmacy chain executives told a recent conference.
Curb Your Enthusiasm: Chinese Pharmas Going Global Hit Speed Bumps
Ambitious and confident Chinese pharmaceutical buyers have begun to enter a new brave world of foreign M&A. However, this scenario can be littered with internal challenges and increasingly external scrutiny, less solid pre-deal asset identification and poor post-deal execution, all of which can damage their barely gained credibility, creating hurdles for future deals.
Betta IPO: New Hope For Made In China Innovation?
The successful IPO of China's drug innovation darling Betta may herald a new wave of capital inflow and renewed interest in new drug R&D in China, but hurdles to the pursuit of original research remain.